Browsing Tag
Merck
101 posts
Merck’s once-daily DOR/ISL HIV therapy delivers sustained viral control and weight stability in Phase 3 results
Discover how Merck’s DOR/ISL HIV therapy preserves viral suppression and metabolic stability, signaling a new era in patient-centered HIV care.
How AstraZeneca’s $4.5bn Virginia investment aligns with Trump-era tariffs and U.S. supply chain policy
Find out how AstraZeneca’s $4.5 billion Virginia API plant could reshape global pharma supply chains and investor sentiment in 2025.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment
Explore Keytruda’s journey from early PD-1 research to global immunotherapy dominance, with clinical, regulatory, and innovation context shaping cancer care in 2025.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Skyhawk Therapeutics and Merck sign $2bn RNA drug discovery pact targeting neurological disorders
Skyhawk Therapeutics inks $2B Merck deal to develop RNA-targeted neurology drugs, highlighting splicing modulation as a new frontier.
What makes Ohtuvayre different from Spiriva or Trelegy? Inside the science of dual inhibition
How is Ohtuvayre different from Spiriva and Trelegy? Discover why Merck’s dual PDE3/PDE4 inhibition could change COPD treatment standards.
Will Merck’s Ohtuvayre pricing strategy face EU pushback during HTA reviews?
Will EU payers push back on Merck’s Ohtuvayre pricing? Find out how HTA reviews may shape COPD access, margins, and the drug’s long-term European rollout.
Can fixed-dose combinations make Ohtuvayre Merck’s next billion-dollar respiratory franchise?
Can a fixed-dose combo turn Ohtuvayre into Merck’s next billion-dollar COPD franchise? Find out how lifecycle strategy may reshape respiratory care.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.